Newsfeeds Archive - Spark Newswire

2 minute read

What’s Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?

June 17, 11:47 AM

Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-5948 showed promising safety and efficacy in Phase 1a/b trials for relapsed/refractory B-cell malignancies

AZN

1 minute read

Lululemon Athletica Was Among The Worst-Performing Stocks Last Week (May 19-May 26, 2024): Are These 10 Large-Cap Stock Losers In Your Portfolio?

By Lekha Gupta

May 26, 11:16 AM

10 worst-performing large-cap stocks last week. National Grid, James Hardie, KE Holdings, JD.Com, XP, Nordson, BeiGene, Lululemon, Walgreens, and Li Auto.

BEKE

2 minute read

Tracking Last Week’s Top Performers: Are These 15 Large-Cap Stocks In Your Portfolio? (April 21-27)

By Lekha Gupta

April 28, 6:18 PM

Last week's top performers included Vertiv Holdings, Tesla, Tyler Technologies, and Newmont Corporation.

3 minute read

Analyst Ratings

Evaluating BeiGene: Insights From 6 Financial Analysts

By Benzinga Insights

April 24, 2:01 PM

In the last three months, 6 analysts have published ratings on BeiGene (NASDAQ:BGNE), offering a diverse range of…

BGNE

2 minute read

HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday

By Avi Kapoor

April 23, 10:50 AM

U.S. stocks were higher, with the Nasdaq Composite gaining over 200 points on Tuesday. Shares of HealthStream, Inc.…

3 minute read

Analyst Ratings

4 Analysts Assess BeiGene: What You Need To Know

By Benzinga Insights

March 27, 11:00 AM

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on BeiGene (NASDAQ:BGNE)…

BGNE

2 minute read

Hang Seng Index Set For Global Expansion With Prada, XPeng, And BeiGene On The Horizon

By Benzinga Neuro

February 16, 7:19 AM

This development comes at a time when the city is grappling with a declining market.

BGNE

1 minute read

JP Morgan’s Bullish View On This Chinese Biotech, Says Pullback Creates Entry Point

By Vandana Singh

February 6, 3:37 PM

BeiGene's JP Morgan coverage highlights upside in valuation post-pullback. Brukinsa's success and Tevimbra's potential add to the optimism. Overweight rating, $185 price target.

BGNE

3 minute read

As China’s Population Declines In 2023, Will Aging Demographics Boost Healthcare Stocks?

By Neil Dennis

January 10, 10:22 AM

Exploring the economic implications of China's declining population on property markets and the potential rise of healthcare and tech investments.

BABA

4 minute read

Uncategorized

HBM gets health boost from drug licensing deals

By The Bamboo Works

December 22, 2:11 PM

Key Takeaways: Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech for an initial sum of $53 million and milestone payments of up to $1.05 billion

BGNE